News
-
-
-
-
PRESS RELEASE
EQS-Adhoc: Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights
Marinomed Biotech AG evaluates a possible 10% capital increase excluding statutory subscription rights to finance ongoing costs in restructuring proceedings. Management Board to discuss with selected investors for potential transaction -
-
PRESS RELEASE
Marinomed Biotech AG reports preliminary financial figures for the first half of 2024
Marinomed Biotech AG reports preliminary financial figures for the first half of 2024, including a decline in revenues compared to 2023. The company aims to stabilize through restructuring and new partnerships -
-
-
-
PRESS RELEASE
Marinomed Biotech AG aims for financial reorganization by restructuring proceedings without self-administration
Marinomed Biotech AG to undergo financial reorganization through restructuring proceedings without self-administration. Application filed as liquidity needs could not be met promptly